Vor Biopharma Inc. Common Stock

VORNASDAQ • USD
ThemeHealthcare - Oncology›Cell & Gene Therapy for Cancer
18.33 USD
↗ 0.07 (0.38%)AT CLOSE (03:59 PM EDT)
18.33
↘ 0.01 (0.03%)
POST MARKET (AS OF 07:31 PM EDT)
Post Market
AS OF 07:31 PM EDT
18.33
↘ 0.01 (0.03%)
🔴Market: CLOSED

Shares of Vor Biopharma Inc. Common Stock (VOR) are trading at $18.34. Technicals currently rate "Neutral" while our fundamental analysis reads "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics suggest VOR is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Oct 26, 2026.

Open?$18.33
High?$18.44
Low?$17.70
Prev. Close?$18.26
Volume?470.3K
Avg. Volume?1.2M
VWAP?$18.12
Rel. Volume?0.40x
Bid / Ask
Bid?$17.80 × 400
Ask?$18.40 × 500
Spread?$0.60
Midpoint?$18.10
Valuation & Ratios
Market Cap?1.1B
Shares Out?59.2M
Float?42.2M
Float %?71.4%
P/E Ratio?1.73
P/B Ratio?-5.42
EPS?$10.61
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
Themes
Healthcare - Oncology›Cell & Gene Therapy for CancerBiotech - Drug Development›Clinical-Stage Platforms
Employees
76
Market Cap
1.1B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.vorbio.com
Listed
2021-02-05
Address
500 BOYLSTON STREET
BOSTON, MA 02116
Phone: 617-655-6580
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
65
Short Sent.?
45
Piotroski F-Score?0/9Weak
Altman Z-Score?-3.11Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?17.63%High
Short Interest?7.4M
Days to Cover?9.0
Free Float42.2M
Avg Daily Volume830.5K
Settlement Date2026-10-15
Financial Health
Current Ratio?19.15Strong
Quick Ratio?19.15Strong
Cash Ratio?4.35Strong
Debt/Equity?-0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
Peers
100
S&P
97
1.7CHEAP▾
P/B?
S&P
97
-5.42CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-6.6CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-313.6%WEAK▾
ROA?
Peers
50
S&P
97
130.5%STRONG▾
Cash Flow & Enterprise
FCF?$-140813000
Enterprise Value?$976.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist